VSA-012

The complement system is an important component of the innate immune system. Abnormal activation, inadequate regulation and control of the complement system, as well as impaired and dysfunctional effector functions, underlie complement mediated diseases. VSA012 targeting complement system has the potential to treat a variety of diseases associated with abnormal activation of the complement system (e.g. PNH) .The purpose of VSA012-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VSA012 Injection in adult healthy volunteers (HVs). HVs will receive a single dose of VSA012 or placebo.

主要目的： 评价VSA012在中国补体相关性肾病受试者中的有效性； 评价VSA012在中国补体相关性肾病受试者中的安全性和耐受性。 次要目的： 评价VSA012在中国补体相关性肾病受试者中的药代动力学（PK）特征； 评价VSA012在中国补体相关性肾病受试者中的药效学（PD）特征。